Edition:
India

Integra LifeSciences Holdings Corp (IART.OQ)

IART.OQ on NASDAQ Stock Exchange Global Select Market

52.26USD
16 Feb 2018
Change (% chg)

$0.83 (+1.61%)
Prev Close
$51.43
Open
$51.28
Day's High
$52.55
Day's Low
$51.28
Volume
427,322
Avg. Vol
189,628
52-wk High
$56.39
52-wk Low
$40.51

Latest Key Developments (Source: Significant Developments)

Integra Lifesciences Announces Preliminary Q4 Earnings Per Share View $0.55, Revenue View $351.0
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Integra Lifesciences Holdings Corp ::- ‍ORGANIC REVENUE GROWTH IN Q4 IS EXPECTED TO BE ABOUT 5.5%, ABOVE COMPANY'S IMPLIED GUIDANCE OF ABOUT 4%​.- ‍IS STILL EVALUATING IMPACT OF TAX CUTS AND JOBS ACT OF 2017 ON ITS GAAP FINANCIAL RESULTS​.INTEGRA LIFESCIENCES ANNOUNCES PRELIMINARY FOURTH QUARTER 2017 FINANCIAL RESULTS.SEES Q4 2017 REVENUE ABOUT $365 MILLION.Q4 EARNINGS PER SHARE VIEW $0.55, REVENUE VIEW $351.0 MILLION -- THOMSON REUTERS I/B/E/S.INTEGRA LIFESCIENCES-Q4 2017 ADJUSTED EPS, EXCLUDING IMPACT FROM TAX CUTS,JOBS ACT OF 2017,TO EXCEED HIGH-END OF PREVIOUS GUIDANCE RANGE OF $0.53 TO $0.57.  Full Article

Integra Lifesciences Holdings Corp ‍Reaffirms 2017 Financial Guidance As Provided On Oct 26, 2017​
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Integra Lifesciences Holdings Corp ::- ‍REAFFIRMING 2017 FINANCIAL GUIDANCE AS PROVIDED ON OCTOBER 26, 2017​.- ‍REAFFIRMING 2018 ADJUSTED EARNINGS PER SHARE IN RANGE OF $2.25 TO $2.35​.INTEGRA LIFESCIENCES SAYS PROVIDING 2018 PRELIMINARY REVENUE ESTIMATE IN RANGE OF $1.46 BILLION TO $1.48 BILLION - SEC FILING.INTEGRA LIFESCIENCES - ESTABLISHING FIVE-YEAR FINANCIAL TARGETS OF ABOUT $2 BILLION IN REVENUE AND AN ADJUSTED EBITDA MARGIN RANGE OF 28% TO 30%.FY2018 EARNINGS PER SHARE VIEW $2.30 -- THOMSON REUTERS I/B/E/S.FY2017 EARNINGS PER SHARE VIEW $1.85, REVENUE VIEW $1.17 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Capital Research Global Investors Reports 11.1 Pct Passive Stake In Integra Lifesciences As Of Nov 30
Saturday, 9 Dec 2017 

Dec 8 (Reuters) - Integra Lifesciences Holdings Corp ::CAPITAL RESEARCH GLOBAL INVESTORS REPORTS 11.1 PERCENT PASSIVE STAKE IN INTEGRA LIFESCIENCES HOLDINGS CORP AS OF NOVEMBER 30 - SEC FILING.  Full Article

Integra Lifesciences Q3 adjusted earnings per share $0.45
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Integra Lifesciences Holdings Corp ::Integra Lifesciences reports third quarter 2017 financial results.Q3 adjusted earnings per share $0.45.Q3 GAAP earnings per share $0.04.Q3 revenue $279 million versus I/B/E/S view $286.1 million.Q3 earnings per share view $0.47 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $1.83 to $1.87.Sees FY 2017 gaap earnings per share $0.24 to $0.30.Sees FY 2017 revenue $1.165 billion to $1.175 billion.Integra Lifesciences Holdings Corp - "‍we expect some storm-related disruptions to continue to impact revenues in Q4"​.Integra Lifesciences Holdings Corp - ‍full-year 2017 organic revenue growth is now expected to be about 4 pct​.FY2017 earnings per share view $1.91, revenue view $1.15 billion -- Thomson Reuters I/B/E/S.  Full Article

Integra Lifesciences says Depuy Synthes entitled to get termination fee of $60 million if co fails to complete deal
Wednesday, 15 Feb 2017 

Integra Lifesciences Holdings Corp : Depuy Synthes entitled to get termination fee of $60 million if co fails to complete deal after conditions to closing are satisfied .Depuy Synthes to pay termination fee of $41.8 million if co terminates deal due to Depuy Synthes’S breach of exclusivity obligations.  Full Article

Integra Lifesciences plans to acquire Codman neurosurgery business from Johnson & Johnson for $1.045 bln
Wednesday, 15 Feb 2017 

Integra Lifesciences Holdings Corp : Integra Lifesciences plans to acquire the Codman neurosurgery business from Johnson & Johnson for $1.045 billion in cash . Deal for $1.045 billion in cash . Transaction expected to be accretive to integra's adjusted earnings per diluted share by at least $0.22 in first fy . Says expects codman neurosurgery revenue to experience some initial disruption in first year of combination . Says expects codman neurosurgery revenue to grow 3% to 6% longer term . Says has obtained committed financing, subject to customary closing conditions, from BofA Merrill Lynch and JPMorgan .Deal expected to also accelerate path to achieving co's aspirational targets of $2 billion in revenue, 30% adjusted ebitda margin.  Full Article

Integra Lifesciences sees 2016 sales $992 mln-$1.002 bln
Thursday, 28 Jul 2016 

Integra Lifesciences Holdings Corp : Raising its FY gaap and adjusted eps guidance by $0.04/share and narrowing guidance range to new range of $1.78 - $1.88 and $3.43 - $3.53, respectively . Integra lifesciences reports second quarter 2016 financial results . Q2 adjusted earnings per share $0.79 . Q2 gaap earnings per share $0.32 . Q2 revenue $249.3 million versus i/b/e/s view $243.2 million . Sees fy 2016 sales $992 million to $1.002 billion . Q2 earnings per share view $0.76 -- Thomson Reuters I/B/E/S . Integra lifesciences holdings corp says q2 gaap gross margin was 64.1% and adjusted gross margin was 69.2% . Integra lifesciences holdings corp says raising organic sales guidance to 9%. For 2016 .FY2016 earnings per share view $3.44, revenue view $994.8 million -- Thomson Reuters I/B/E/S.  Full Article

Integra Lifesciences Holdings Corp raises low end of prior guidance range
Wednesday, 27 Apr 2016 

Integra Lifesciences Holdings Corp:Raising low end of FY 2016 revenue guidance to a new range of $985 million to $1.0 billion, up from prior guidance of $975 million to $1.0 billion.Raises Fy 2016 organic revenue growth to about 8% from its previous guidance of about 7%.Adjusts low end of its FY 2016 adjusted earnings per share guidance range to $3.38 - $3.50 from $3.35 - $3.50.Says the company's GAAP EPS guidance is now $1.73 to $1.85.  Full Article

BRIEF-Integra Lifesciences Announces Preliminary Q4 Earnings Per Share View $0.55, Revenue View $351.0

* - ‍ORGANIC REVENUE GROWTH IN Q4 IS EXPECTED TO BE ABOUT 5.5%, ABOVE COMPANY'S IMPLIED GUIDANCE OF ABOUT 4%​